2 results
Approved WMOPending
Our primary aim is to assess the (cost-)effects of the ACCESS system in the support of exacerbation self-management of patients with COPD.
Approved WMORecruiting
Primary objective: To estimate the difference in anti-proliferative activity of LEE011 600 mg QD and LEE011 400 mg QD in combination with letrozole 2.5 mg QD vs single agent letrozole 2.5 mg QD as measured by changes in Ki-67 levels from baseline to…